UROGEN PHARMA LTD (URGN) Stock Analyst Ratings
USA - NASDAQ:URGN - IL0011407140 - Common Stock
23.76 USD
-0.16 (-0.67%)
23.76 USD
0 (0%)
ChartMill assigns a Buy % Consensus number of 84% to URGN. The Buy consensus is the weighted average rating of the current analysts ratings.
Analysts have set a mean price target forecast of 34.42. This target is 44.89% above the current price.
URGN was analyzed by 14 analysts. The buy percentage consensus is at 84. So analysts seem to be very confident about URGN.
In the previous month the buy percentage consensus was at a similar level.
URGN was analyzed by 14 analysts, which is quite many. So the average rating should be quite meaningful.
Price Target & Forecast
| Date | Firm | Action | Rating |
|---|---|---|---|
| 2025-10-27 | D. Boral Capital | Maintains | Buy -> Buy |
| 2025-10-27 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2025-10-03 | D. Boral Capital | Maintains | Buy -> Buy |
| 2025-08-19 | Piper Sandler | Initiate | Overweight |
| 2025-08-11 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2025-08-07 | D. Boral Capital | Maintains | Buy -> Buy |
| 2025-08-05 | D. Boral Capital | Maintains | Buy -> Buy |
| 2025-07-08 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2025-07-07 | D. Boral Capital | Maintains | Buy -> Buy |
| 2025-06-13 | Guggenheim | Maintains | Buy -> Buy |
| 2025-06-13 | ScotiaBank | Maintains | Sector Outperform -> Sector Outperform |
| 2025-06-12 | D. Boral Capital | Maintains | Buy -> Buy |
| 2025-06-03 | Oppenheimer | Maintains | Outperform -> Outperform |
| 2025-05-23 | Guggenheim | Maintains | Buy -> Buy |
| 2025-05-22 | Goldman Sachs | Maintains | Neutral -> Neutral |
| 2025-05-22 | HC Wainwright & Co. | Downgrade | Buy -> Neutral |
| 2025-05-13 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2025-05-12 | D. Boral Capital | Maintains | Buy -> Buy |
| 2025-05-08 | D. Boral Capital | Maintains | Buy -> Buy |
| 2025-04-29 | Guggenheim | Reiterate | Buy -> Buy |
| 2025-04-28 | D. Boral Capital | Maintains | Buy -> Buy |
| 2025-04-28 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2025-04-17 | Goldman Sachs | Maintains | Neutral -> Neutral |
| 2025-04-16 | ScotiaBank | Initiate | Sector Outperform |
| 2025-03-13 | D. Boral Capital | Maintains | Buy -> Buy |
| 2025-03-11 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2025-03-10 | D. Boral Capital | Maintains | Buy -> Buy |
| 2025-02-25 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2025-02-20 | D. Boral Capital | Maintains | Buy -> Buy |
| 2025-02-18 | D. Boral Capital | Maintains | Buy -> Buy |
UROGEN PHARMA LTD / URGN FAQ
Can you provide the average price target for UROGEN PHARMA LTD stock?
14 analysts have analysed URGN and the average price target is 34.42 USD. This implies a price increase of 44.89% is expected in the next year compared to the current price of 23.76.
What is the consensus rating for URGN stock?
The consensus rating for UROGEN PHARMA LTD (URGN) is 84.2857 / 100 . This indicates that analysts generally have a positive outlook on the stock.
Can you provide the analyst count for UROGEN PHARMA LTD stock?
The number of analysts covering UROGEN PHARMA LTD (URGN) is 14.